BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote in favor of your Favored sort of footwear - 2The Best 15 Applications for Efficiency and Association
- 3SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- 4Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- 5Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Must-See Public Parks from Around the Globe
- Vote in favor of your Number one method for praising a birthday
- The Green Transformation: 5 Feasible Living Practices
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- 4 Must-Visit bar-b-que Eateries This Year
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- Telescope in Chile captures stunning new picture of a cosmic butterfly
